Placebo oral suspension

DRUG4 trials

Sponsors

Corcept Therapeutics, Columbia University, Glock Health, Science and Research GmbH, Tampere University Hospital

Conditions

Antibiotic Resistant InfectionChronic CoughCritical IllnessHealthyLead ExposureNosocomial InfectionNutrition DisordersPathogen Transmission

Phase 1

First-in-human Study in Healthy Subjects

CompletedNCT03315338

Corcept TherapeuticsHealthy

Start: 2017-09-15End: 2019-02-22Updated: 2019-05-24

Phase 2

Inulin for Infections in the Intensive Care Unit

CompletedNCT03865706

Columbia UniversityAntibiotic Resistant Infection, Critical Illness, Nosocomial Infection +3

Start: 2019-10-14End: 2024-07-23Updated: 2025-06-19

Phase 3

Finnish Children´s Protracted Cough

RecruitingNCT07582549

Tampere University HospitalChronic Cough

Start: 2025-12-22End: 2027-12-01Target: 100Updated: 2026-05-13

Unknown Phase

G-PUR® for Reduced Lead Bioavailability

CompletedNCT04138693

Glock Health, Science and Research GmbHLead Exposure

Start: 2019-09-24End: 2020-02-12Updated: 2020-06-04

Related Papers

Gut Colonization With Vancomycin-Resistant <i>Enterococcus</i> Shapes the Gut Microbiome in the Intensive Care Unit

The Journal of Infectious Diseases2025-04-141 citations

A phase 2 randomized, placebo-controlled trial of inulin for the prevention of gut pathogen colonization and infection among patients admitted to the intensive care unit for sepsis.

2025-01-135 citations

Concomitant oral intake of purified clinoptilolite tuff (G-PUR) reduces enteral lead uptake in healthy humans

Scientific Reports2021-07-2017 citations